地区销售经理（福建）
上海中信国健医药发展有限公司
- 公司规模：500-1000人
- 公司性质：合资
- 公司行业：制药/生物工程
职位信息
- 发布日期：2017-02-03
- 工作地点：福州
- 招聘人数：1人
- 学历要求：大专
- 职位月薪：8000-15000/月
- 职位类别：医药销售经理/主管
职位描述
职位描述：
举报
分享
地区销售经理
岗位目的：根据大区业务规划，制定省区日常销售计划，分配销售指标，并督促落实和达成；收集分析市场信息，上报大区经理，以作为决策依据；依据公司相关制度和规定，对销售人员进行宣贯和培训，确保销售人员行为合规。
主要职责：
1、 根据大区业务规划，制定省区销售计划，分解销售指标，并督促落实和反馈；
2、 收集市场信息，关注VIP客户动态，执行区域市场推广活动；
3、 针对所辖省区销售团队，开展销售能力培训，确保团队成员高效执行，行为合规，完成所辖人员日常招聘、考核、培训等工作，并及时进行沟通和反馈；
4、 完成上级领导交办的其他工作。
任职资格：
1、大专及以上，市场营销专业，有临床医学、药学等相关专业背景优先；
2、5年医药行业工作经验，至少3年（2年）区域销售管理经验；
3、掌握药品市场销售特性与销售方法，熟悉市场营销、人力资源管理知识；
4、精通产品知识、了解医学及药物学等专业知识；
5、熟悉医药行业市场及医药行业方面的国家政策、法律、法规；
6、优秀的市场管理能力（市场信息分析能力、计划执行、客户关系维护、市场策划及销售策略制定、资源分配）；
7、优秀的团队管理能力，较强的自我管理能及沟通与商务谈判技能。
职能类别： 医药销售经理/主管
关键字： 销售经理；医药
公司介绍
上海中信国健医药发展有限公司
上海中信国健医药发展有限公司为上海中信国健药业股份有限公司全资子公司。
上海中信国健药业股份有限公司（以下简称“中信国健”）是由中国中信集团有限公司旗下中信泰富有限公司投资控股的生物医药高新技术企业。公司自2002年创建以来，专注于抗体药物的研发、中试和产业化，现已发展成为国内抗体制药领域的领军企业，提供覆盖治疗肿瘤、自身免疫性疾病、抗器官移植排斥反应等重大疾病领域的靶向药物。
作为一家以研发为基础的生物制药公司，中信国健已成功构建了抗体药物开发和产业化平台并掌握核心技术，具备持续开发新药的创新能力。公司生产规模位居行业前列。
Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio -pharmaceutical company which is co-invested and led by China International Trust and Investment Corporation (CITIC) Group. CPGJ focuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China’s domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ’s strategic planning. The company’s product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation and Autoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in the biological anti-rheumatic drugs field in China.
Dedicated to sharpening its Research & Development capability, CPGJ has successfully produced key technological know-hows for the development and industrialization of monoclonal antibody drugs. As CPGJ’s wholly owned R&D organization, Biotechnology Institute of Shanghai CP Guojian focuses on discovery and early development of therapeutic antibodies and proteins, as well as innovation of technologies and processes to support drug development. The institute has established a comprehensive technological platform with a strong capability to take a drug development program from early discovery through CMC stage.
现由于公司发展需要，诚聘具有创新精神和成就事业理想的优秀人才加盟。
请符合条件的应聘者将中英文简历等信息发送E-mail至：cpgjhr@cpgj-pharm.com （请在邮件题目上注明应聘职位等信息）
上海中信国健医药发展有限公司为上海中信国健药业股份有限公司全资子公司。
上海中信国健药业股份有限公司（以下简称“中信国健”）是由中国中信集团有限公司旗下中信泰富有限公司投资控股的生物医药高新技术企业。公司自2002年创建以来，专注于抗体药物的研发、中试和产业化，现已发展成为国内抗体制药领域的领军企业，提供覆盖治疗肿瘤、自身免疫性疾病、抗器官移植排斥反应等重大疾病领域的靶向药物。
作为一家以研发为基础的生物制药公司，中信国健已成功构建了抗体药物开发和产业化平台并掌握核心技术，具备持续开发新药的创新能力。公司生产规模位居行业前列。
Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio -pharmaceutical company which is co-invested and led by China International Trust and Investment Corporation (CITIC) Group. CPGJ focuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China’s domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ’s strategic planning. The company’s product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation and Autoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in the biological anti-rheumatic drugs field in China.
Dedicated to sharpening its Research & Development capability, CPGJ has successfully produced key technological know-hows for the development and industrialization of monoclonal antibody drugs. As CPGJ’s wholly owned R&D organization, Biotechnology Institute of Shanghai CP Guojian focuses on discovery and early development of therapeutic antibodies and proteins, as well as innovation of technologies and processes to support drug development. The institute has established a comprehensive technological platform with a strong capability to take a drug development program from early discovery through CMC stage.
现由于公司发展需要，诚聘具有创新精神和成就事业理想的优秀人才加盟。
请符合条件的应聘者将中英文简历等信息发送E-mail至：cpgjhr@cpgj-pharm.com （请在邮件题目上注明应聘职位等信息）
联系方式
- Email：cpgjhr@cpgj-pharm.com
- 公司地址：上班地址：泰安